Phase transfer catalyzed alkylation of phenylacetonitrile and its derivatives with dimeric quaternary ammonium compounds
Is this your thesis?
This record came from a bulk archive import. If it’s yours, link it to your profile.
Abstract (EN)
One of the most significant application areas of green chemistry is phase-transfer catalysis. Monomeric quaternary ammonium salts, such as tetrabutylammonium bromide, are frequently employed as phase-transfer catalysts in organic synthesis reactions involving Phase Transfer Catalysis. In recent years, it has been noted that dimeric quaternary ammonium compounds exhibit superior surface-active properties compared to their monomeric analogues. Therefore, it is reasonable to assume that dimeric quaternary ammonium compounds may offer improved performance in phase-transfer catalyzed organic syntheses relative to monomeric counterparts. Verapamil, which is used in the treatment of cardiac arrhythmia and hypertension; Sibutramine, an anti-obesity and antidepressant drug; and Anastrozole, an effective medication for the treatment of advanced postmenopausal breast cancers, all involve the phase-transfer catalyzed alkylation of phenylacetonitriles as a key intermediate step in their synthesis. In this study, the phase-transfer catalyzed alkylation of phenylacetonitrile and its derivatives was investigated using dimeric quaternary ammonium salts (gemini surfactants) as catalysts. For this purpose, quaternary ammonium-type gemini surfactants with varying spacer chain lengths (n = 2, 6, 10) and hydrophobic alkyl chain lengths (R = 10, 12, 16) were first synthesized. Subsequently, the synthesized gemini surfactants were employed as phase-transfer catalysts in the alkylation of phenylacetonitrile and its derivatives, namely 3,4-dimethoxyphenylacetonitrile and 4-(trifluoromethyl)phenylacetonitrile. The yields obtained using the gemini surfactants were compared with those achieved using the classical phase-transfer catalyst tetrabutylammonium bromide (TBAB). In the presence of gemini surfactants, phase-transfer catalyzed C-alkylation of phenylacetonitrile and its derivatives with primary alkyl halides resulted in highly complex product mixtures, yielding inefficient outcomes. However, when 1,5-dibromopentane was used as the alkyl halide, the formation of a six-membered ring was observed, prompting the study to evolve towards cycloalkylation. Cycloalkylation reactions of phenylacetonitrile, 3,4-dimethoxyphenylacetonitrile, and 4-(trifluoromethyl)phenylacetonitrile in the presence of gemini surfactants provided yields comparable to those obtained with TBAB, with some gemini surfactants exhibiting even superior performance. The structures of the synthesized compounds were characterized by FTIR, 1H NMR, 13C NMR, and mass spectrometry. These results demonstrate that gemini surfactants can be employed as phase-transfer catalysts in the cycloalkylation of phenylacetonitrile and its derivatives, representing a promising alternative to conventional quaternary ammonium salts for such transformations.
Author
Özgem Yazıcı
How to Cite
Özgem Yazıcı (Master Thesis). Phase transfer catalyzed alkylation of phenylacetonitrile and its derivatives with dimeric quaternary ammonium compounds, 2025, Trakya University.
Keywords
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Trakya University
- Tekirdağ şartlarında ıspanak yetiştiriciliğinde farklı ekim zamanı ve bitki sıklığının gelişme ve verim üzerine etkisi(1995)
- The examination of gifted children in terms of psychological, social, and emotional characteristics(2024)
- Teaching science to 6th grade students with intellectual disability: 5E teaching model enriched with different methods and techniques(2024)
- Organs in Bosnian and Turkish idioms(2024)
- Genotoxicity of quinclorac herbicide and protective effect of rosmarinic acid on gill tissue of adult zebrafish (Danio rerio, Hamilton 1822)(2024)
- Dosimetric evaluation of treatment plans made with images gained from cone beam CT in patients with head and neck cancer undergoing adaptive radiotherapy(2024)